Rethinking Immunity to Create a Better Future
At Naz Therapeutics, Inc., we are dedicated to advancing cancer treatment through targeted immunotherapies. Discover our key areas of focus and how our innovative solutions are making a difference.
Targeting FCRLA
Our primary focus is on the anti-FCRLA antibody, a novel approach designed to specifically target and combat B-cell malignancies. This therapy aims to restore the body's natural anti-tumor immunity by targeting FCRLA and its ability to blind the body's immune cells.
Restoring anti-tumor immunity
We are dedicated to understanding and reversing the mechanisms that allow B-cell malignancies to evade the immune system. Our research centers on reactivating the body's defenses to fight cancer effectively.
Pioneering a new class of immunotherapy for B-cell lymphoma
At Naz Therapeutics, Inc., we are advancing a first-in-class immunooncology pipeline built around a newly discovered extracellular immune checkpoint in B-cell lymphoma. Our lead program, NAZ-101, neutralizes secreted FCRLA to restore critical immune responses within the lymphoma microenvironment.
Transforming cancer treatment with innovative immunotherapies
Naz Therapeutics, Inc. is advancing a first-in-class immunooncology pipeline built around a newly discovered extracellular immune checkpoint in B-cell lymphoma. Our lead program, NAZ-101, is designed to neutralize secreted FCRLA and restore endogenous HLA class II antigen presentation and CD4⁺ T-cell activation within the lymphoma microenvironment. This work positions Naz Therapeutics distinctly among early-stage immuno-oncology companies, pursuing first-in-class validation of an entirely new class of extracellular immune checkpoint, with a clear translational path from target discovery to an IND-ready development candidate.
